HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GeneLink distribution deal

This article was originally published in The Tan Sheet

Executive Summary

Start-up direct marketer NuGenix expects to begin selling customized nutritional products developed using GeneLink technology in Q3. Under distribution agreement announced May 8, NuGenix will use GeneLink's patented DNA Collection Kit and nutragenetic assessment system to provide its network of distributors with a customized nutritional regimen consisting initially of approximately six formulas; supplements will be developed and manufactured by Vitaquest division Garden State Nutritionals (1"The Tan Sheet" Oct. 8, 2001, p. 14). Philadelphia-based NuGenix is hoping to attract distributors from other direct marketers both inside and outside the supplement industry...

You may also be interested in...



Genetic Technology Enters Supplement Industry With GSN, GeneLink Deal

Garden State Nutritionals will offer five dietary supplements tailored for consumers' varying genetic capacities to combat certain types and degrees of oxidative stress, according to the firm.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel